Literature DB >> 7814631

On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies.

M D Smirnov1, D T Triplett, P C Comp, N L Esmon, C T Esmon.   

Abstract

Phosphatidylethanolamine (PE) is an important membrane component for supporting activated protein C anticoagulant activity but has little influence on prothrombin activation. This difference constitutes a potential mechanism for selective inhibition of the protein C anticoagulant pathway by lupus anticoagulants and/or antiphospholipid antibodies. In this study, we demonstrate that the presence of PE augments lupus anticoagulant activity. In the plasma of some patients with lupus anticoagulants, activated protein C anticoagulant activity is more potently inhibited than prothrombin activation. As a result, in the presence of activated protein C and PE, these patient plasmas clot faster than normal plasma. Patients with minimal lupus anticoagulant activity are identified whose plasma potently inhibits activated protein C anticoagulant activity. This process is also PE dependent. In three patient plasmas, these phenomena are shown to be due to immunoglobulins. The PE requirement in the expression of activated protein C anticoagulant activity and the PE dependence of some antiphospholipid antibodies provide a mechanistic basis for the selective inhibition of the protein C pathway. Inhibition of activated protein C function may be a common mechanism contributing to increased thrombotic risk in certain patients with antiphospholipid antibodies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7814631      PMCID: PMC295433          DOI: 10.1172/JCI117657

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  33 in total

1.  Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant.

Authors:  R Cariou; G Tobelem; C Soria; J Caen
Journal:  N Engl J Med       Date:  1986-05-01       Impact factor: 91.245

Review 2.  Lupus anticoagulants.

Authors:  S S Shapiro; P Thiagarajan
Journal:  Prog Hemost Thromb       Date:  1982

3.  An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity--a mechanism for thrombosis.

Authors:  J M Freyssinet; M L Wiesel; J Gauchy; B Boneu; J P Cazenave
Journal:  Thromb Haemost       Date:  1986-06-30       Impact factor: 5.249

4.  Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: evidence for a prothrombotic state.

Authors:  J S Ginsberg; C Demers; P Brill-Edwards; M Johnston; R Bona; R F Burrows; J Weitz; J A Denburg
Journal:  Blood       Date:  1993-06-01       Impact factor: 22.113

5.  Anticoagulant protein C pathway defective in majority of thrombophilic patients.

Authors:  J H Griffin; B Evatt; C Wideman; J A Fernández
Journal:  Blood       Date:  1993-10-01       Impact factor: 22.113

6.  Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?

Authors:  J D Oosting; R H Derksen; I W Bobbink; T M Hackeng; B N Bouma; P G de Groot
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

7.  Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems.

Authors:  J Rauch; M Tannenbaum; H Tannenbaum; H Ramelson; P R Cullis; C P Tilcock; M J Hope; A S Janoff
Journal:  J Biol Chem       Date:  1986-07-25       Impact factor: 5.157

8.  Changes in membrane phospholipid distribution during platelet activation.

Authors:  E M Bevers; P Comfurius; R F Zwaal
Journal:  Biochim Biophys Acta       Date:  1983-12-07

9.  Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants.

Authors:  W Shi; B H Chong; C N Chesterman
Journal:  Blood       Date:  1993-03-01       Impact factor: 22.113

10.  Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant.

Authors:  P Thiagarajan; S S Shapiro; L De Marco
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

View more
  20 in total

1.  Cardiolipin is a normal component of human plasma lipoproteins.

Authors:  H Deguchi; J A Fernandez; T M Hackeng; C L Banka; J H Griffin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 2.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 3.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 4.  Lantibiotics as probes for phosphatidylethanolamine.

Authors:  Ming Zhao
Journal:  Amino Acids       Date:  2009-11-22       Impact factor: 3.520

5.  Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset.

Authors:  N Nakamura; T Ban; K Yamaji; Y Yoneda; Y Wada
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

Review 6.  Diagnosis and management of the antiphospholipid syndrome.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Blood Rev       Date:  2017-07-30       Impact factor: 8.250

7.  Effects of membrane and soluble EPCR on the hemostatic balance and endotoxemia in mice.

Authors:  Xunzhen Zheng; Weihong Li; Jian-Ming Gu; Dongfeng Qu; Gary L Ferrell; Naomi L Esmon; Charles T Esmon
Journal:  Blood       Date:  2006-10-05       Impact factor: 22.113

Review 8.  Mechanisms of antiphospholipid-induced thrombosis: effects on the protein C system.

Authors:  Denis Wahl; Aurélie Membre; Christine Perret-Guillaume; Véronique Regnault; Thomas Lecompte
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

9.  Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

Authors:  R Simantov; J M LaSala; S K Lo; A E Gharavi; L R Sammaritano; J E Salmon; R L Silverstein
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

10.  Phosphatidylethanolamine at the luminal endothelial surface--implications for hemostasis and thrombotic autoimmunity.

Authors:  Clive W Wells; Paula E North; Suresh Kumar; Christine B Duris; John A McIntyre
Journal:  Clin Appl Thromb Hemost       Date:  2009-11-10       Impact factor: 2.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.